Sun Pharma Q1FY27 Sales Up 10.1% to ₹151,836 Million; Net Profit at ₹28,948 Million
Sun Pharma reported Q1 FY27 consolidated sales of ₹151,836 million, up 10.1% YoY. Net profit rose to ₹28,948 million. India formulation sales grew 16% to ₹54,749 million. Global Innovative Medicines sales increased 12.8% to US$ 351 million. The acquisition of Organon & Co. is on track to close in early 2027.
The announcement includes key financial results (sales, profit), segment-wise performance, R&D updates, and significant corporate actions (acquisition progress), all of which are material for investors and stakeholders.
The company reported positive year-on-year growth in sales and net profit, along with strong performance in key markets like India and Innovative Medicines. The progress on the Organon acquisition also adds to the positive outlook.
Sun Pharmaceutical Industries Limited announced its financial results for the first quarter ended June 30, 2026, reporting consolidated sales of ₹151,836 million, a growth of 10.1% year-on-year. The company's net profit for the quarter stood at ₹28,948 million.
Global Innovative Medicines sales reached US$ 351 million, an increase of 12.8%, and contributed 21.9% to the total sales. EBITDA was reported at ₹44,177 million, with an EBITDA margin of 28.9%. Adjusted net profit saw a rise of 3.1% to ₹30,894 million. Research and Development (R&D) investment for the quarter was ₹8,264 million, representing 5.4% of sales.
Formulation sales in India grew by 16% to ₹54,749 million, accounting for 36.1% of consolidated sales, maintaining Sun Pharma's position as India's No. 1 Pharma Company with an increased market share of 8.5%. In the US, formulation sales were US$ 427 million, a decrease of 9.7%, with growth in Innovative Medicines partially offsetting the decline in generics. Emerging Markets formulations sales increased by 4.2% to US$ 311 million, and Rest of World formulations sales were US$ 218 million.
The company also provided an update on its R&D pipeline, including five novel entities in clinical stages. The proposed acquisition of Organon & Co. has received approval from Organon shareholders and is on track to close in early 2027. The Board of Directors meeting, which commenced on July 31, 2026, also approved the Unaudited Standalone and Consolidated Financial Results for Q1 FY 2026-27.
What to do with a filing like this
Sun Pharmaceutical Industries Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Sun Pharmaceutical Industries Limited. Read the original for the full detail.